Jing Wang - CanSino Biologics Insider
| CJH Stock | EUR 3.98 0.04 1.02% |
Insider
Jing Wang is Vice President - Finance and Capital Markets, Secretary of The Board of CanSino Biologics since 2020.
| Age | 42 |
| Tenure | 4 years |
| Phone | 400 922 2099 |
| Web | https://www.cansinotech.com |
CanSino Biologics Management Efficiency
The company has return on total asset (ROA) of (0.0207) % which means that it has lost $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0111 %, meaning that it generated $0.0111 on every $100 dollars invested by stockholders. CanSino Biologics' management efficiency ratios could be used to measure how well CanSino Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pavel Cheussov | JSC Halyk bank | N/A | |
| Sarah Medina | The Hanover Insurance | N/A | |
| BSc FAusIMM | Perseus Mining Limited | N/A | |
| Jennifer Luisa | The Hanover Insurance | N/A | |
| P Condron | The Hanover Insurance | 73 | |
| Gayle Falvey | The Hanover Insurance | N/A | |
| Zhumabek Mamutov | JSC Halyk bank | 41 | |
| James Kelley | The Hanover Insurance | N/A | |
| Olga Vuros | JSC Halyk bank | N/A | |
| Denise Lowsley | The Hanover Insurance | 47 | |
| FCIS FGIA | Perseus Mining Limited | N/A | |
| Nariman Mukushev | JSC Halyk bank | N/A | |
| Martin Hughes | The Hanover Insurance | 69 | |
| FRM CFA | JSC Halyk bank | 50 | |
| Jessica Volich | Perseus Mining Limited | N/A | |
| Dauren Sartayev | JSC Halyk bank | 41 | |
| Lindsay Greenfield | The Hanover Insurance | N/A | |
| Scott Grieco | The Hanover Insurance | N/A | |
| Aivar Bodanov | JSC Halyk bank | 61 | |
| Roman Maszczyk | JSC Halyk bank | N/A | |
| Matthew Mitchell | The Hanover Insurance | N/A | |
Management Performance
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 |
CanSino Biologics Leadership Team
Elected by the shareholders, the CanSino Biologics' board of directors comprises two types of representatives: CanSino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CanSino. The board's role is to monitor CanSino Biologics' management team and ensure that shareholders' interests are well served. CanSino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CanSino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Zhu Tao, Chief Scientific Officer, Deputy General Manager, Executive Director | ||
| Yonghui Wu, VP Marketing | ||
| WingYu Leung, Non-Executive Director | ||
| Jianzhong Liu, Independent Non-Executive Director | ||
| FCS FCIS, Joint Sec | ||
| Dongxu Qiu, Senior Vice President Deputy General Manager, Executive Director | ||
| Qiang Xu, Non-Executive Director | ||
| Jing Wang, Vice President - Finance and Capital Markets, Secretary of The Board | ||
| Huihua Mao, Senior Vice President Deputy General Manager | ||
| Zhu Xin, Non-Executive Independent Director | ||
| Jin Cui, Joint Company Secretary | ||
| Xuefeng Yu, Executive Chairman of the Board, Chief Executive Officer, General Manager | ||
| Tao Zhu, Ex CoFounder | ||
| Chunlin Xin, Director Department | ||
| Shuifa Gui, Independent Non-Executive Director | ||
| Xi Luo, Chief Officer | ||
| Liang Lin, Non-Executive Director | ||
| Shiu Wai, Non-Executive Independent Director | ||
| Ming Chiu, Joint Company Secretary | ||
| Dongxu MBA, Exec CoFounder | ||
| Xiao Zhi, Non-Executive Independent Director | ||
| ShouBai Chao, COO Director | ||
| Shou Chao, Chief Operating Officer, Deputy General Manager, Executive Director |
CanSino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CanSino Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Current Valuation | 3.4 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.77 % | |||
| Price To Book | 2.36 X | |||
| Price To Sales | 2.21 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 1.03 B |
Currently Active Assets on Macroaxis
Other Information on Investing in CanSino Stock
CanSino Biologics financial ratios help investors to determine whether CanSino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.